1. Home
  2. CERS vs NKTX Comparison

CERS vs NKTX Comparison

Compare CERS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$1.98

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.82

Market Cap

247.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERS
NKTX
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.0M
247.4M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
CERS
NKTX
Price
$1.98
$2.82
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
1.0M
937.7K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
11.88
EPS
N/A
N/A
Revenue
$51,326,000.00
N/A
Revenue This Year
$19.95
N/A
Revenue Next Year
$8.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.68
N/A
52 Week Low
$1.15
$1.63
52 Week High
$2.96
$3.65

Technical Indicators

Market Signals
Indicator
CERS
NKTX
Relative Strength Index (RSI) 52.85 55.53
Support Level $1.93 $1.88
Resistance Level $2.15 N/A
Average True Range (ATR) 0.10 0.27
MACD 0.01 0.03
Stochastic Oscillator 47.54 45.72

Price Performance

Historical Comparison
CERS
NKTX

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: